Join to view full profile
2090 Springdale RdSte DCherry Hill, NJ 08003
Phone+1 877-388-2778
Fax+1 856-582-7686
Dr. Brown is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Rutgers Health/New Jersey Medical SchoolResidency, Urology, 1998 - 2003
Rowan University School of Osteopathic MedicineClass of 1998
Certifications & Licensure
FL State License 2022 - 2028
NJ State License 1999 - 2027
AZ State License 2021 - 2026
CA State License 2021 - 2026
TX State License 2004 - 2010
AOA Board of Surgery Urological Surgery
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification athenaClinicals, athenahealth, Inc., 2012, 2014-2017
- CMS Meaningful Use Stage 1 Certification ALLSCRIPTS PROFESSIONAL EHR, Allscripts, 2012, 2014-2017
- CMS Meaningful Use Stage 1 Certification Allscripts Professional EHR, Allscripts, 2012, 2014-2017
Publications & Presentations
PubMed
- Real-World PSA Response and Overall Survival Among Men with mCSPC Receiving Apalutamide Versus Darolutamide (Both Without Docetaxel) in the US.Mehmet A Bilen, Gordon Brown, Mukul Singhal, Carmine Rossi, Dominic Pilon
Advances in Therapy. 2026-07-28 - 1 citationsHomologous Recombination Repair Mutations, Next-generation Sequencing Testing, and Treatment Progression by Race Among Patients With Metastatic Castration-sensitive Pr...Mehmet A Bilen, Neal Shore, Sabree Burbage, Carmine Rossi, Lilian Diaz
Urology. 2026-05-01 - Comparison of deep prostate-specific antigen response in Black patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or enzalutamide.Benjamin H Lowentritt, Sabree Burbage, Ibrahim Khilfeh, Dominic Pilon, Shawn Du
Journal of Comparative Effectiveness Research. 2026-02-01
Press Mentions
Case 1: Non-Muscle Invasive, BCG-Refractory Bladder CancerNovember 27th, 2019
High Response Rates with Gene Therapies for BCG-Unresponsive Bladder CancerMay 5th, 2024
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
